Xencor, Inc. (XNCR) Stock Price & How to Invest

Xencor, Inc. engineers antibodies. Its XmAb platform makes small, deliberate changes to an antibody's Fc region and binding domains, altering how long the molecule persists in the body, how strongly it recruits immune cells, or whether it can grip two targets at once. The company licenses those engineered domains to larger drugmakers and runs its own pipeline from Pasadena, California. Partnered products already carry the technology into approved medicines, with royalties arriving from Alexion on Ultomiris and from Incyte on tafasitamab, and Zenas BioPharma filed a US application for obexelimab in IgG4-related disease in May 2026 that triggered a ~$10 million milestone to Xencor in June.

The investment picture in August 2026 is dominated by two anti-TL1A programs for inflammatory bowel disease. Shares changed hands near ~$29 against a 52-week range of roughly ~$7.71 to ~$29.42, putting the market capitalisation around ~$2.2 billion on trailing revenue of about ~$105 million. Cash, equivalents and marketable debt securities stood at ~$486.4 million on June 30, 2026, down from ~$610.8 million at the end of 2025, and management guides to ending 2026 with ~$420 million to ~$440 million and to funding operations through 2028. Quarterly research spending of ~$71.9 million against lumpy, milestone-driven revenue is what consumes that balance, so the valuation is being set by clinical expectations rather than by the income statement.

Every meaningful catalyst here is binary. A disappointing blinded interim on XmAb942, or induction data in 2027 that fails to separate from what Merck has already shown with tulisokibart, would remove the reason most of the current market capitalisation exists. The TL1A field is crowded with far better-funded rivals, including Merck, which paid $10.8 billion for Prometheus to acquire the lead asset, plus Roche, Sanofi with Teva, and AbbVie with FutureGen, so being second or third to market with a similar mechanism is a real commercial outcome. Cash guidance of through-2028 assumes the current plan holds, and a broadened Phase 3 program or a slower partnering environment could force dilution at whatever price the stock happens to be. Losing the US Ultomiris royalty stream permanently narrows the non-dilutive funding base just as spending rises.

12 analysts publish price targets on XNCR, averaging $29.00 against a $29.00 price as of August 2026, or +0.0%. The published targets run from $14.00 to $44.00, a wide spread, and the ratings split 12 buy, 2 hold, 0 sell. Over the last six months there have been 5 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full XNCR forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Xencor, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The TL1A franchise carries the equity story. XmAb942, an anti-TL1A antibody engineered for extended dosing intervals, is in the XENITH-UC study in ulcerative colitis, with a blinded interim analysis expected around the end of 2026 and the 12-week induction endpoint in the second half of 2027. The most optimistic published target, $44.00, assumes this works close to its best case.

The case against. Every meaningful catalyst here is binary. The most pessimistic target, $14.00, is roughly what XNCR is worth if this bites instead.

Read the full bull and bear case on XNCR, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Xencor, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$105 million
• Revenue (Q2 2026): ~$51.2 million, up from ~$43.6 million a year earlier
• R&D expense (Q2 2026): ~$71.9 million
• Net loss (first half 2026): ~$150.6 million, or ~$1.99 per share
• Cash and marketable securities (June 30, 2026): ~$486.4 million, guided to ~$420 to ~$440 million at year end
• Market capitalisation: ~$2.2 billion on ~74.4 million shares

Conventional multiples do not describe this business well. Backing out roughly ~$486 million of cash leaves an enterprise value near ~$1.7 billion against trailing revenue of about ~$105 million, and that revenue is partly one-off settlement and milestone money rather than a repeatable run rate. Earnings multiples do not apply at all while the company loses money by design, so the practical comparison is enterprise value against the addressable market the TL1A programs would reach if they work.

Other names that sit close to XNCR: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get XNCR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so XNCR sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where XNCR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Xencor pairs a genuine royalty stream and a cash pile funded into 2028 with an equity value that now rests almost entirely on whether its TL1A antibodies read out well.

Whether XNCR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is XNCR a buy or a sell?, and where the stock could go from here in the XNCR stock forecast.

For income investors, whether XNCR pays a dividend and how the payout looks is covered in does XNCR pay a dividend? And to weigh XNCR against a peer, read the full side-by-side comparisons: XNCR vs SNY and XNCR vs ABBV.